Alpha Tau Medical Ltd

Research Alpha Tau Medical Ltd (DRTS) on Bullrun: market cap USD 1.36B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 1.36B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 42.63M-USD 32.76Mn/a-0.53USD 12.20MUSD 13.73MUSD 77.10M
FY2024USD 0-USD 31.75M-USD 22.02Mn/a-0.45USD 13.72MUSD 12.54MUSD 62.67M
FY2023USD 0-USD 29.16M-USD 24.36Mn/a-0.42USD 12.66MUSD 13.28MUSD 84.48M
FY2022USD 0-USD 33.76M-USD 24.78Mn/a-0.53USD 5.84Mn/aUSD 105.66M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 1.36Bn/an/an/a
20252025-12-31USD 435.65Mn/an/an/a
20242024-12-31USD 218.18Mn/an/an/a
20232023-12-29USD 209.12Mn/an/an/a
20222022-12-30USD 219.46Mn/an/an/a

About Alpha Tau Medical Ltd

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Alpha Tau Medical Ltd's market cap?

Alpha Tau Medical Ltd's market capitalization is USD 1.36B.

What does Alpha Tau Medical Ltd do?

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer.